UA85699C2 - 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists - Google Patents

6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists

Info

Publication number: UA85699C2
Authority: UA; Ukraine
Prior art keywords: azepines; benzo; tetrahydro; substituted; receptor agonists
Prior art date: 2004-02-25

Application number

UAA200609265A

Other languages

English (en)

Inventor

Джон Гордон Аллен

Карин Брайнер

Майкл Филип Коуэн

Кристофер Стенли Галка

Сара Линн Хеллман

Мария Анхелес Мартинес-Грау

Метью Роберт Рейнхард

Майкл Джон Родригес

Роджер Райан Ротхар

Майкл Уейд Тидуэлл

Франтц Виктор

Эндрю Сирвин Вильямс

Деи Чжан

Стивен Армен Бойд

Ричард Джерард Конуей

Арундхати С. Део

Уэй-Ман Ли

Кристофер Стивен Сидем

Аджай Сингх

Михаэль П. Мазанетц

Original Assignee

Эли Лилли Энд Компани

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-25

Filing date

2005-02-18

Publication date

2009-02-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34910927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA85699(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-02-18 Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани

2009-02-25 Publication of UA85699C2 publication Critical patent/UA85699C2/ru

Links

102000006902 5-HT2C Serotonin Receptor Human genes 0.000 title abstract 2
108010072553 5-HT2C Serotonin Receptor Proteins 0.000 title abstract 2
-1 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines Chemical class 0.000 title abstract 2
239000000018 receptor agonist Substances 0.000 title abstract 2
229940044601 receptor agonist Drugs 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
208000019901 Anxiety disease Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Gynecology & Obstetrics (AREA)
Child & Adolescent Psychology (AREA)
Addiction (AREA)
Pregnancy & Childbirth (AREA)
Anesthesiology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)

UAA200609265A 2004-02-25 2005-02-18 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists UA85699C2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US54768104P	2004-02-25	2004-02-25

Publications (1)

Publication Number	Publication Date
UA85699C2 true UA85699C2 (en)	2009-02-25

Family

ID=34910927

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200609265A UA85699C2 (en)	2004-02-25	2005-02-18	6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists

Country Status (29)

Country	Link
US (2)	US8022062B2 (ru)
EP (2)	EP2479168B1 (ru)
JP (1)	JP4796047B2 (ru)
KR (1)	KR100848411B1 (ru)
CN (3)	CN102329267A (ru)
AR (1)	AR048242A1 (ru)
AU (1)	AU2005217602B2 (ru)
BR (1)	BRPI0507986A (ru)
CA (1)	CA2556390C (ru)
CL (1)	CL2010001292A1 (ru)
CR (1)	CR8566A (ru)
DK (1)	DK1720836T3 (ru)
DO (1)	DOP2005000024A (ru)
EA (1)	EA011011B1 (ru)
EC (1)	ECSP066788A (ru)
ES (2)	ES2466641T3 (ru)
IL (1)	IL177267A (ru)
MA (1)	MA28486B1 (ru)
MY (1)	MY141992A (ru)
NO (1)	NO20064277L (ru)
NZ (2)	NZ549009A (ru)
PE (1)	PE20060010A1 (ru)
PL (1)	PL1720836T3 (ru)
PT (1)	PT1720836E (ru)
SI (1)	SI1720836T1 (ru)
SV (1)	SV2005002025A (ru)
UA (1)	UA85699C2 (ru)
WO (1)	WO2005082859A1 (ru)
ZA (1)	ZA200606580B (ru)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1632494A1 (en)	2004-08-24	2006-03-08	Ferring B.V.	Vasopressin v1a antagonists
EP1924560B1 (en) *	2005-09-01	2009-08-05	Eli Lilly And Company	6-substituted- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
JP5249031B2 (ja) *	2005-09-01	2013-07-31	イーライリリーアンドカンパニー	５−ＨＴ２Ｃ受容体アゴニストとしての６−Ｎ結合型へテロ環置換された２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン
BRPI0615033A2 (pt)	2005-09-01	2011-04-26	Lilly Co Eli	composto, composição farmacêutica, e, uso de um composto
BRPI0615048A2 (pt) *	2005-09-01	2010-03-30	Lilly Co Eli	composto, composição farmacêutica, e, uso de um composto
EP2018863B9 (en)	2006-05-16	2015-02-18	Takeda Pharmaceutical Company Limited	Fused heterocyclic compound and use thereof
WO2007140213A1 (en)	2006-05-26	2007-12-06	Forest Laboratories Holdings Limited	Pyridoazepine derivatives
AU2007283113A1 (en)	2006-08-08	2008-02-14	Sanofi-Aventis	Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
EP2789338A3 (en)	2007-11-15	2015-01-14	Takeda Pharmaceutical Company Limited	Condensed pyridine derivate and use thereof
JP5491421B2 (ja)	2008-03-04	2014-05-14	アリーナファーマシューティカルズ，インコーポレイテッド	５−ｈｔ２ｃアゴニストである（ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンに関連する中間体の調製のためのプロセス
UY31968A (es)	2008-07-09	2010-01-29	Sanofi Aventis	Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
CN101712675B (zh) *	2008-10-07	2013-07-03	江苏恒谊药业有限公司	苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用
WO2010065446A2 (en) *	2008-12-01	2010-06-10	The Procter & Gamble Company	Perfume systems
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011012622A1 (en)	2009-07-30	2011-02-03	Glaxo Group Limited	Benzoxazinone derivatives for the treatment of glytl mediated disorders
KR20120060207A (ko)	2009-08-26	2012-06-11	사노피	신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
EP2504316A1 (en)	2009-11-23	2012-10-03	MSD Oss B.V.	Heterocylic compounds as antagonists of the orexin receptors
US20110269744A1 (en)	2010-03-12	2011-11-03	Astellas Pharma Inc.	Benzazepine Compound
WO2011153206A1 (en)	2010-06-02	2011-12-08	Arena Pharmaceuticals, Inc.	Processes for the preparation of 5-ht2c receptor agonists
WO2012030957A2 (en)	2010-09-01	2012-03-08	Arena Pharmaceuticals, Inc.	Non-hygroscopic salts of 5-ht2c agonists
CN103347523A (zh)	2010-09-01	2013-10-09	艾尼纳制药公司	向具有肾损伤的个体给药氯卡色林
KR20180118801A (ko)	2010-09-01	2018-10-31	에자이 알앤드디 매니지먼트 가부시키가이샤	체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
US20130267500A1 (en)	2010-09-01	2013-10-10	Arena Pharmaceuticals, Inc.	5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
SG188363A1 (en) *	2010-09-01	2013-04-30	Arena Pharm Inc	Fast-dissolve dosage forms of 5-ht2c agonists
MX2013002422A (es) *	2010-09-01	2013-05-17	Arena Pharm Inc	Sales de lorcaserina con acidos opticamente activos.
JP5809157B2 (ja)	2010-10-08	2015-11-10	持田製薬株式会社	環状アミド誘導体
EP2683702B1 (de)	2011-03-08	2014-12-24	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de)	2011-03-08	2014-12-17	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120058A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de)	2011-03-08	2016-06-01	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8871758B2 (en)	2011-03-08	2014-10-28	Sanofi	Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
CA2834465A1 (en)	2011-04-28	2012-11-01	Mochida Pharmaceutical Co., Ltd.	Cyclic amide derivative
WO2012152741A1 (de)	2011-05-10	2012-11-15	Bayer Intellectual Property Gmbh	Bicyclische (thio)carbonylamidine
CN103030604A (zh) *	2011-10-10	2013-04-10	上海医药工业研究院	4-烷基-5-甲酰基噻唑或5-甲酰基噻唑的制备方法
CN103145619A (zh) *	2012-06-15	2013-06-12	史慎德	7-氯-6-苯磺酰氨基-2,3,4,5-四氢-1H-苯并[d]氮杂*的制备
WO2014058441A1 (en)	2012-10-09	2014-04-17	Arena Pharmaceuticals, Inc.	Method of weight management
JP6440625B2 (ja)	2012-11-14	2018-12-19	ザ・ジョンズ・ホプキンス・ユニバーシティー	精神分裂病を処置するための方法および組成物
EP2801575A1 (en)	2013-05-07	2014-11-12	Bayer CropScience AG	Heteroaryldihydropyridine derivatives as fungicides
WO2015066344A1 (en)	2013-11-01	2015-05-07	Arena Pharmaceuticals, Inc.	5-ht2c receptor agonists and compositions and methods of use
CN103864679B (zh) *	2014-03-21	2015-11-18	河南师范大学	一种3-甲基-2-吡啶甲酸甲酯的制备方法
CN104193656B (zh) *	2014-09-09	2016-01-06	太原理工大学	一种β-二羰基砜类化合物及其制备方法
CN105622511B (zh) *	2014-11-03	2018-01-23	北京瑞都医药科技有限公司	一种减肥药物及其制备方法
CN104496891A (zh) *	2014-12-06	2015-04-08	哈尔滨工业大学	吡啶衍生物2-叔丁氧基-6-亚甲基氯吡啶的合成方法
EP3288933B1 (en)	2015-04-30	2021-10-06	Musc Foundation for Research Development	Oxindole compounds and pharmaceutical compositions thereof
MX384391B (es)	2015-05-22	2025-03-14	Agenebio Inc	Composiciones farmacéuticas de levetiracetam de liberación extendida.
CN110621669A (zh)	2017-05-04	2019-12-27	巴斯夫欧洲公司	防除植物病原性真菌的取代5-卤代烷基-5-羟基异噁唑类
US20210052600A1 (en)	2017-12-27	2021-02-25	Takeda Pharmaceutical Company Limited	Therapeutic agents for stress urinary incontinence and incotinence of feces
CA3127789A1 (en)	2019-02-01	2020-08-06	Fmc Corporation	Diamino-substituted pyridines and pyrimidines as herbicides
EP3976610A1 (en)	2019-05-29	2022-04-06	Syngenta Crop Protection AG	Microbiocidal derivatives
CA3157848A1 (en) *	2019-10-14	2021-04-22	The Regents Of The University Of California	Broad spectrum anti-cancer compounds
BR112022021228A2 (pt)	2020-04-26	2022-12-06	Jiangsu Nhwa Pharmaceutical Co Ltd	Derivado da 1,5-di-hidro-2,4-benzodiazepin-3-ona e aplicação do mesmo
AR131541A1 (es)	2023-01-07	2025-04-09	Syngenta Crop Protection Ag	Compuestos de carboxamida novedosos
WO2025109114A1 (en)	2023-11-24	2025-05-30	Syngenta Crop Protection Ag	Novel carboxamide compounds
WO2025149637A1 (en)	2024-01-12	2025-07-17	Syngenta Crop Protection Ag	Novel carboxamide compounds
WO2025149629A1 (en)	2024-01-12	2025-07-17	Syngenta Crop Protection Ag	Novel carboxamide compounds
WO2026008750A1 (en)	2024-07-05	2026-01-08	Syngenta Crop Protection Ag	Novel carboxamide compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2265890A (en) *	1939-11-25	1941-12-09	Arrow Hart & Hegeman Electric	Combined face plate and receptacle
US4265890A (en) *	1978-07-07	1981-05-05	Smithkline Corporation	6-Phenyl thio- and 6-cyclohexyl thio-2,3,4,5-tetrahydro-1H-3-benzazepines
ZA792785B (en) *	1978-07-07	1980-08-27	Smithkline Corp	Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines
US4349472A (en)	1979-04-27	1982-09-14	Schering Corporation	(S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
EP0285287A3 (en)	1987-03-23	1990-08-16	Smithkline Beecham Corporation	3-benzazepine compounds for use in treating gastrointestinal motility disorders
US4985352A (en)	1988-02-29	1991-01-15	The Trustees Of Columbia University In The City Of New York	DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof
GB9116824D0 (en)	1991-08-05	1991-09-18	Smithkline Beecham Corp	Chemical compounds
GB9119467D0 (en) *	1991-09-12	1991-10-23	Smithkline Beecham Corp	Chemical compounds
CA2150345A1 (en)	1993-09-28	1995-04-06	Makoto Komatsu	Quinoxaline derivative as antidiabetic agent
US5698766A (en)	1995-04-05	1997-12-16	The Regents Of The University Of California	Transgenic animal model for testing drugs for treating eating disorders and epilepsy
EP1183238A1 (en)	1999-05-17	2002-03-06	Eli Lilly And Company	Metabotropic glutamate receptor antagonists
WO2001007416A1 (de)	1999-07-28	2001-02-01	Lonza Ag	Verfahren zur herstellung von pyridazincarbonsäurederivaten
CN1149212C (zh)	1999-09-29	2004-05-12	伊莱利利公司	用作再摄入抑制剂的哌啶衍生物
GB0005789D0 (en)	2000-03-11	2000-05-03	Knoll Ag	Therapeutic agents
EP1213017A3 (en)	2000-12-05	2003-11-12	Akzo Nobel N.V.	Use of a 5-HT2C receptor agonist for the treatment of hot flushes
JPWO2002074746A1 (ja)	2001-03-16	2004-07-08	山之内製薬株式会社	ベンゾアゼピン誘導体
DE60206762T2 (de)	2001-07-13	2006-07-13	Pharmacia & Upjohn Co. Llc, Kalamazoo	Hexahydroazepino(4,5-g)indole und -indoline als 5-ht rezeptor-liganden
MXPA04005151A (es)	2001-11-28	2004-08-11	Upjohn Co	Compuestos terapeuticos.
US6908939B2 (en)	2001-12-21	2005-06-21	Galderma Research & Development S.N.C.	Biaromatic ligand activators of PPARγ receptors
US6953787B2 (en)	2002-04-12	2005-10-11	Arena Pharmaceuticals, Inc.	5HT2C receptor modulators

2005
- 2005-02-18 EA EA200601546A patent/EA011011B1/ru not_active IP Right Cessation
- 2005-02-18 US US10/598,302 patent/US8022062B2/en not_active Expired - Fee Related
- 2005-02-18 NZ NZ549009A patent/NZ549009A/xx not_active IP Right Cessation
- 2005-02-18 JP JP2007500906A patent/JP4796047B2/ja not_active Expired - Fee Related
- 2005-02-18 CN CN2011101821562A patent/CN102329267A/zh active Pending
- 2005-02-18 BR BRPI0507986-1A patent/BRPI0507986A/pt not_active IP Right Cessation
- 2005-02-18 EP EP12161584.3A patent/EP2479168B1/en not_active Expired - Lifetime
- 2005-02-18 NZ NZ586553A patent/NZ586553A/en not_active IP Right Cessation
- 2005-02-18 PL PL05723397T patent/PL1720836T3/pl unknown
- 2005-02-18 UA UAA200609265A patent/UA85699C2/ru unknown
- 2005-02-18 DK DK05723397.5T patent/DK1720836T3/da active
- 2005-02-18 WO PCT/US2005/005418 patent/WO2005082859A1/en not_active Ceased
- 2005-02-18 ES ES05723397.5T patent/ES2466641T3/es not_active Expired - Lifetime
- 2005-02-18 CN CNA2005800057884A patent/CN1934088A/zh active Pending
- 2005-02-18 CN CN2011101820767A patent/CN102311387A/zh active Pending
- 2005-02-18 AU AU2005217602A patent/AU2005217602B2/en not_active Ceased
- 2005-02-18 KR KR1020067019634A patent/KR100848411B1/ko not_active Expired - Fee Related
- 2005-02-18 ES ES12161584.3T patent/ES2468741T3/es not_active Expired - Lifetime
- 2005-02-18 PT PT57233975T patent/PT1720836E/pt unknown
- 2005-02-18 SI SI200531852T patent/SI1720836T1/sl unknown
- 2005-02-18 EP EP05723397.5A patent/EP1720836B1/en not_active Expired - Lifetime
- 2005-02-18 CA CA2556390A patent/CA2556390C/en not_active Expired - Fee Related
- 2005-02-23 DO DO2005000024A patent/DOP2005000024A/es unknown
- 2005-02-24 PE PE2005000219A patent/PE20060010A1/es not_active Application Discontinuation
- 2005-02-24 AR ARP050100686A patent/AR048242A1/es not_active Application Discontinuation
- 2005-02-24 MY MYPI20050730A patent/MY141992A/en unknown
- 2005-02-25 SV SV2005002025A patent/SV2005002025A/es unknown
2006
- 2006-08-03 IL IL177267A patent/IL177267A/en not_active IP Right Cessation
- 2006-08-07 ZA ZA200606580A patent/ZA200606580B/xx unknown
- 2006-08-23 CR CR8566A patent/CR8566A/es unknown
- 2006-08-24 EC EC2006006788A patent/ECSP066788A/es unknown
- 2006-09-21 NO NO20064277A patent/NO20064277L/no not_active Application Discontinuation
- 2006-09-25 MA MA29343A patent/MA28486B1/fr unknown
2010
- 2010-11-25 CL CL2010001292A patent/CL2010001292A1/es unknown
2011
- 2011-07-28 US US13/192,707 patent/US8580780B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NZ586553A (en)	2011-11-25
BRPI0507986A (pt)	2007-07-24
ES2466641T3 (es)	2014-06-10
IL177267A0 (en)	2006-12-10
US20120028961A1 (en)	2012-02-02
EP2479168A1 (en)	2012-07-25
EP1720836A1 (en)	2006-11-15
US8580780B2 (en)	2013-11-12
EA200601546A1 (ru)	2007-02-27
PL1720836T3 (pl)	2014-09-30
CA2556390A1 (en)	2005-09-09
CN102311387A (zh)	2012-01-11
PE20060010A1 (es)	2006-02-11
CL2010001292A1 (es)	2011-07-15
EA011011B1 (ru)	2008-12-30
US8022062B2 (en)	2011-09-20
NO20064277L (no)	2006-11-22
JP4796047B2 (ja)	2011-10-19
SI1720836T1 (sl)	2014-06-30
CN102329267A (zh)	2012-01-25
CA2556390C (en)	2012-10-02
ECSP066788A (es)	2006-11-16
CR8566A (es)	2006-12-01
DOP2005000024A (es)	2005-11-15
ES2468741T3 (es)	2014-06-16
AR048242A1 (es)	2006-04-12
MA28486B1 (fr)	2007-03-01
SV2005002025A (es)	2005-11-04
WO2005082859A1 (en)	2005-09-09
US20090099155A1 (en)	2009-04-16
AU2005217602B2 (en)	2011-02-17
PT1720836E (pt)	2014-07-16
DK1720836T3 (da)	2014-05-05
ZA200606580B (en)	2008-02-27
KR100848411B1 (ko)	2008-07-28
MY141992A (en)	2010-08-16
IL177267A (en)	2011-10-31
EP1720836B1 (en)	2014-04-16
NZ549009A (en)	2010-08-27
JP2007523951A (ja)	2007-08-23
AU2005217602A1 (en)	2005-09-09
EP2479168B1 (en)	2014-04-09
KR20070001200A (ko)	2007-01-03
CN1934088A (zh)	2007-03-21

Publication	Publication Date	Title
UA85699C2 (en)	2009-02-25	6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
WO2007028083A3 (en)	2007-05-18	6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
CY1110531T1 (el)	2015-04-29	6-υποκατεστημενες-2,3,4,5-τετραϋδρο-1η-βενζο[d]αζεπινες ως αγωνιστες του υποδοχεα 5-ht2c
TW200510324A (en)	2005-03-16	6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
WO2007028132A3 (en)	2007-06-07	6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
CY1110486T1 (el)	2015-04-29	6-υποκατασταθεισες 2,3,4,5-τετραϋδρο-1η-βενζο[d]αζεπινες ως συναγωνιστες υποδοχεως 5-ηt2c
TW200503705A (en)	2005-02-01	3-amino chroman and 2-amino tetralin derivatives
GB0504828D0 (en)	2005-04-13	Therapeutic agents
NO20076344L (no)	2008-02-27	Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren
WO2004082584A3 (en)	2004-11-04	5ht2c receptor antagonists in the treatment of schizophrenia
AU2002256334A1 (en)	2002-11-11	Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino(2,3-f)quinoxaline
IL158828A0 (en)	2004-05-12	Novel heteroaryl derivatives, their preparation and use
EP1988902A4 (en)	2009-05-06	PIPERAZIN DERIVATIVES
MXPA03011766A (es)	2004-04-02	Novedosos derivados de indol.
TW200637545A (en)	2006-11-01	Novel uses for estrogen beta agonists
CY1113558T1 (el)	2016-06-22	6-αρυλαλκυλαμινο-2,3,4,5-τετραϋδρο-1η-βενζοδιαζεπινες ως αγωνιστες υποδοχεα 5-ht2c
CY1115160T1 (el)	2016-12-14	6-υποκατεστημενες 2,3,4,5-τετραϋδρο-1η-βενζο [d]αζεπινες ως αγωνιστες υποδοχεα 5-ht2c
DOP2004000972A (es)	2005-02-28	6-(2,2,2-trifluoroetilamino)-7-cloro-2,3,4,5-tetrahidro 1h-benzo[d] azepina como agonista del receptor 5-ht2c